Global Neuroblastoma Drugs Market 2019-2023
SKU ID : TNV-14770482 | Publishing Date : 28-Jan-2019 | No. of pages : 118
Detailed TOC of Global Neuroblastoma Drugs Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Chemotherapy - Market size and forecast 2018-2023
• Immunotherapy - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Improvements in research and development for treatment of relapsed refractory neuroblastoma
• Availability of improved diagnostic modalities
• Rising number of patient support initiatives
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb
• Johnson & Johnson
• Pfizer
• Teva Pharmaceutical
• United Therapeutics
PART 14: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Pipeline molecules for neuroblastoma
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Immunotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Immunotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Decision framework
Exhibit 42: Quarterly sales for UNITUXIN in $ millions
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Novel therapies under research and development for neuroblastoma
Exhibit 45: Patient support initiatives for neuroblastoma
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Bristol-Myers Squibb - Vendor overview
Exhibit 52: Bristol-Myers Squibb - Business segments
Exhibit 53: Bristol-Myers Squibb - Organizational developments
Exhibit 54: Bristol-Myers Squibb - Geographic focus
Exhibit 55: Bristol-Myers Squibb - Key offerings
Exhibit 56: Johnson & Johnson - Vendor overview
Exhibit 57: Johnson & Johnson - Business segments
Exhibit 58: Johnson & Johnson - Organizational developments
Exhibit 59: Johnson & Johnson - Geographic focus
Exhibit 60: Johnson & Johnson - Segment focus
Exhibit 61: Johnson & Johnson - Key offerings
Exhibit 62: Pfizer - Vendor overview
Exhibit 63: Pfizer - Business segments
Exhibit 64: Pfizer - Organizational developments
Exhibit 65: Pfizer - Geographic focus
Exhibit 66: Pfizer - Segment focus
Exhibit 67: Pfizer - Key offerings
Exhibit 68: Teva Pharmaceutical - Vendor overview
Exhibit 69: Teva Pharmaceutical - Business segments
Exhibit 70: Teva Pharmaceutical - Organizational developments
Exhibit 71: Teva Pharmaceutical - Geographic focus
Exhibit 72: Teva Pharmaceutical - Segment focus
Exhibit 73: Teva Pharmaceutical - Key offerings
Exhibit 74: United Therapeutics - Vendor overview
Exhibit 75: United Therapeutics - Business segments
Exhibit 76: United Therapeutics - Organizational developments
Exhibit 77: United Therapeutics - Geographic focus
Exhibit 78: United Therapeutics - Key offerings
Exhibit 79: Validation techniques employed for market sizing
Exhibit 80: List of abbreviations
Keyplayers in Global Neuroblastoma Drugs Market 2019-2023
Bristol-Myers SquibbJohnson & Johnson
Pfizer
Teva Pharmaceutical
and United Therapeutics